A Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Elderly Adults

NCT04822025 ↗

Phase 2 Completed 420 enrolled Medigen Vaccine Biologics Corp.

RandomizedParallel-groupDouble-blindPrevention

Summary

The purpose of this study is to assess the safety and immunogenicity of MVC-COV1901 vaccine in two different dose forms in participants who are generally healthy or with stable pre-existing health conditions.

Timeline

Start: 2021-05-20
Primary completion: 2021-08-25
Completion: 2022-01-28

Publications

Waits A, Chen JY, Cheng WH, Yeh JI, Hsieh SM, Chen C, Janssen R, Lien CE, Lin TY. Safety and immunogenicity of MVC-COV1901 vaccine in older adults: Phase 2 randomized dose-comparison trial. Int J Infect Dis. 2022 Nov;124:21-26. doi: 10.1016/j.ijid.2022.08.021. Epub 2022 Aug 29.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	MVC-COV1901	Vaccine	15 ug	Intramuscular
Subject	MVC-COV1901	Vaccine	25 ug	Intramuscular

Indications

No indication recorded.